Select Biotechnology Portfolio
Fidelity Select Portfolios · 1 share class
Fund classification
Classified from what the fund holds · as of 2026 Q2
Select Biotechnology Portfolio is an actively managed U.S. equity fund.
- Asset class
- Equity
- Region
- United States
- Management
- Actively managed
- Fund type
- Open-end fund
- Features
- Non-diversified
Fund profile
As filed in the prospectus · 2026 Q2
Biotechnology Portfolio seeks capital appreciation.
The fund invests at least 80% of assets in common stocks of companies principally engaged in biotechnology research, development, manufacturing, and distribution, including those focused on genetic analysis and genetic engineering, selected through fundamental analysis of financial condition, industry position, and market conditions. The fund may invest in both domestic and foreign issuers. Because the fund's classification of companies as principally engaged in biotechnology relies on asset, income, sales, or profit metrics or third-party industry classifications, the fund's holdings may diverge from what different analysts would consider core biotechnology exposure.
| Share class | Expense ratio |
|---|---|
| FBIOX | 0.62% |
Portfolio turnover 45.00% · as of 2026 Q2
Allocation
Asset groups · long / short shown separately, never netted · 2026 Q2
| Stocks | 99.89% |
| Cash & short-term | 3.51% |
Sector allocation
The same holdings as Allocation above, grouped by market sector instead of asset type · as of 2026 Q2
| Health Care | 83.0% |
| International | 11.7% |
| Cash | 3.4% |
| Other | 1.7% |
| Industrials | 0.2% |
Government, Securitized and Cash are non-corporate buckets; International is foreign holdings we don’t sector-classify, and Other is the residual (held funds, unresolved names).
Latest quarter
What changed since the fund's previous filing
Largest new: ASCENDIS PHARMA A/S, CELC, VTRS, RLAY, KLRA, TYRA, COAG, CITY THERAPEUTICS INC
Largest exited: ASCENDIS PHARMA A/S, CENTESSA PHARMACEUTICALS PLC, TERNS PHARMACEUTICALS INC, SOLENO THERAPEUTICS INC, BIO TUB HOLDINGS LLC, ORUKA THERAPEUTICS INC, ENGENE HOLDINGS INC, SCORPION THERAPEUTICS INC
Return profile
Total return as filed — price change plus distributions reinvested · trailing figures to Apr 2026
May 2026 has been filed since the trailing figures were struck, so it is not in the table above or the curve — every figure here shares one cut-off, which is what makes them comparable with other funds.
Holdings
By % of NAV · equity positions carry filed share counts · every resolvable issuer links to its company page
| Ticker | Issuer | %NAV | Reported price | Value | Shares |
|---|---|---|---|---|---|
| KRYS | KRYSTAL BIOTECH INCKRYS | 10.58% | $309.03 | $557.06M | 1.8M |
| ABBV | ABBVIE INCABBV | 9.22% | $217.72 | $485.56M | 2.2M |
| AMGN | AMGEN INCAMGN | 6.53% | $336.79 | $343.86M | 1.0M |
| GILD | GILEAD SCIENCES INCGILD | 4.82% | $134.43 | $253.58M | 1.9M |
| — | Fidelity Revere Street Trust | 3.35% | — | $176.49M | — |
| ALNY | ALNYLAM PHARMACEUTICALS INCALNY | 2.93% | $301.98 | $154.52M | 511.7K |
| PRAX | PRAXIS PRECISION MEDICINES INC.PRAX | 2.47% | $349.97 | $129.99M | 371.4K |
| INSM | INSMED INCINSM | 2.25% | $106.91 | $118.58M | 1.1M |
| ARGX | ARGENX SEARGX | 2.25% | $835.99 | $118.25M | 141.4K |
| — | ASCENDIS PHARMA A/S | 2.04% | $224.11 | $107.66M | 480.4K |
Reported price is the fund's own reported value divided by its own reported shares at 2026-05-31 — not a live quote, and not what the fund paid.
Top 10 positions are 46.44% of net assets, top 25 66.15%, across 191 issuers.
See more of this fund's book
More positions with filed share counts, and the quarter-over-quarter change list rather than the largest few — free with an account, no card required.
Sign in free